Market Herald logo


Be the first with the news that moves the market

Pro Medicus Limited has signed the seven-year contract between subsidiary Visage Imaging and Duke Health.

The contract will see the use of Pro Medicus’ Visage 7 technology being used across Duke’s radiology departments and its electronic health record. The Visage 7 delivers a multi-display, multi-dimensional and referring physician platform to access diagnostic imaging modalities.

It allows radiologists and physicians to interpret images, CT scans, brain scans, and vessel analysis. This technology will offer a faster and more streamlined analysis for health professionals.

Pro Medicus CEO Dr. Sam Hupert believes this partnership will be beneficial to their progress.

“This partnership not only helps consolidate our strong position in this highly competitive market, but it also enables us to leverage our development and commercialisation efforts across an increasing base of academic and research orientated clients,” he said.

Visage 7 will be used across three hospitals and dozens of other locations including the Duke University Hospital.

Is planned to begin rolling out at the end of 2019 with the first sites to implement at the beginning of 2020.

Please find announcement here

PME by the numbers
More From The Market Herald
The Market Herald Video

" Opthea (ASX:OPT) secures up to US$260m in funding for OPT-302 trials

Opthea (ASX:OPT) secures up to US$170 million in financing and a US$90 million placement to advance…
Creso Pharma (ASX:CPH) -

" Creso Pharma’s (ASX:CPH) ImpACTIVE appoints new brand ambassador

Creso Pharma's (ASX:CPH) subsidiary, ImpACTIVE has appointed multi-sport performance coach Kolby Tullier as brand ambassador.
The Market Herald Video

" Proteomics International (ASX:PIQ) to raise $8m for Promarker development

Proteomics International (ASX:PIQ) receives firm commitments to raise $8 million to advance marketing, sales and further…
The Market Herald Video

" Paradigm Biopharmaceuticals (ASX:PAR) taps investors for $66m to fund future developments

Paradigm Biopharmaceuticals (ASX:PAR) taps investors for $66 million to fund developments into the 2024 calendar year.